Published in Drug Discov Today Dis Models on June 27, 2012
Engineering therapeutic antibodies targeting G-protein-coupled receptors. Exp Mol Med (2016) 0.78
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 12.18
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
Beta-arrestins and cell signaling. Annu Rev Physiol (2007) 8.65
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol (2006) 7.84
Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med (1982) 6.79
Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev (2001) 6.50
Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov (2008) 6.18
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation (1993) 4.52
Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A (2003) 3.99
Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res (1993) 3.87
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A (2007) 3.82
The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol (2009) 3.55
Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest (2007) 3.15
Vascular adrenoceptors: an update. Pharmacol Rev (2001) 2.83
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature (1991) 2.53
beta-arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem (2007) 2.51
Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A (2005) 2.48
The 7 TM G-protein-coupled receptor target family. ChemMedChem (2006) 2.00
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res (2008) 1.87
Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem (1993) 1.87
Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther (2010) 1.87
Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol (2002) 1.84
Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature (1991) 1.83
Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation (2003) 1.70
Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A (2008) 1.67
The pharmacology of carvedilol. Eur J Clin Pharmacol (1990) 1.67
ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol (1994) 1.66
Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol (1992) 1.56
Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res (2010) 1.52
Modelling G-protein-coupled receptors for drug design. Biochim Biophys Acta (1999) 1.50
beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal (2010) 1.45
The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev (2011) 1.39
Beta-adrenoceptors in cardiac disease. Pharmacol Ther (1993) 1.37
Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med (2005) 1.36
Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest (1994) 1.33
Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension (1995) 1.32
GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol (2010) 1.31
Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail (2011) 1.24
Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation (1994) 1.22
Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation (1990) 1.21
Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem (2010) 1.20
Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res (2011) 1.19
beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem (2009) 1.17
G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res (2011) 1.14
Cardiac myocyte necrosis induced by angiotensin II. Circ Res (1991) 1.13
Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol (2010) 1.11
Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol (2008) 1.10
Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem (1998) 1.06
Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci Signal (2011) 1.05
Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol (2011) 1.03
The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol (2007) 1.00
β₂ AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol (2010) 1.00
Functional selectivity in adrenergic and angiotensin signaling systems. Mol Pharmacol (2010) 0.99
Identification and characterization of guinea pig angiotensin II ventricular and atrial receptors: coupling to inositol phosphate production. Circ Res (1988) 0.98
GPCR expression in the heart; "new" receptors in myocytes and fibroblasts. Trends Cardiovasc Med (2004) 0.98
G-protein coupled receptor signaling in myocardium: not for the faint of heart. Physiology (Bethesda) (2007) 0.98
Angiotensin II activates endothelial constitutive nitric oxide synthase via AT1 receptors. Hypertens Res (1996) 0.95
Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J Clin Invest (1990) 0.95
betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease. J Cardiovasc Transl Res (2010) 0.94
Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep (2004) 0.90
Identification and characterization of the rabbit angiotensin II myocardial receptor. Circ Res (1984) 0.89
Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. Drug Discov Today Dis Mech (2010) 0.88
Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits. J Mol Cell Cardiol (2011) 0.88
Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol (2010) 0.88
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker. Expert Rev Cardiovasc Ther (2012) 0.86
Characterization of the rabbit ventricular myocardial receptor for angiotensin II. Evidence for two sites of different affinities and specificities. Mol Pharmacol (1983) 0.85
Dual action of angiotensin II on coronary resistance in the isolated perfused rabbit heart. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.84
beta-Adrenergic blockers: a 50-year historical perspective. Am J Ther (2009) 0.82
Knocking out angiotensin II in the heart. Curr Hypertens Rep (2011) 0.80
Regulation of G protein function: implications for heart disease. Mol Cell Biochem (1996) 0.79
Extended-release metoprolol succinate in chronic heart failure. Ann Pharmacother (2003) 0.78
Cardiac production of angiotensin II and its pharmacologic inhibition: effects on the coronary circulation. Mayo Clin Proc (1999) 0.78
Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies. Curr Heart Fail Rep (2011) 0.78
Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J (2003) 0.78
Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart. Exp Physiol (2009) 0.77
Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension. J Cardiovasc Pharmacol (1990) 0.77
Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 2.08
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy. Circ Res (2008) 1.87
Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II. J Biol Chem (2008) 1.85
Epac-mediated activation of phospholipase C(epsilon) plays a critical role in beta-adrenergic receptor-dependent enhancement of Ca2+ mobilization in cardiac myocytes. J Biol Chem (2006) 1.82
GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hypertension. Circulation (2012) 1.71
Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation (2006) 1.67
Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res (2005) 1.57
Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res (2010) 1.52
Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res (2009) 1.47
Inhibiting p90 ribosomal S6 kinase prevents (Na+)-H+ exchanger-mediated cardiac ischemia-reperfusion injury. Circulation (2006) 1.46
Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. Circ Res (2005) 1.41
A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A (2005) 1.34
CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol (2006) 1.31
Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. J Card Fail (2006) 1.28
New approaches in small animal echocardiography: imaging the sounds of silence. Am J Physiol Heart Circ Physiol (2011) 1.20
Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop. Circ Res (2007) 1.16
Phospholipase Cε hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell (2013) 1.14
G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res (2011) 1.14
PAR-1 contributes to the innate immune response during viral infection. J Clin Invest (2013) 1.09
A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability. J Biol Chem (2007) 1.08
Identification of Nogo as a novel indicator of heart failure. Physiol Genomics (2007) 1.03
Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol (2010) 1.00
β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation (2012) 0.97
An endogenously produced fragment of cardiac myosin-binding protein C is pathogenic and can lead to heart failure. Circ Res (2013) 0.96
Mammalian enabled (Mena) is a critical regulator of cardiac function. Am J Physiol Heart Circ Physiol (2011) 0.94
Cardiac overexpression of Mammalian enabled (Mena) exacerbates heart failure in mice. Am J Physiol Heart Circ Physiol (2013) 0.88
Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunits. J Mol Cell Cardiol (2011) 0.88
Cyclophilin A promotes cardiac hypertrophy in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2011) 0.88
Nebulette mutations in cardiac remodeling: big effects from a small mechanosensor. J Am Coll Cardiol (2010) 0.86
Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease. Chest (2005) 0.86
Cardiac intercellular communication: are myocytes and fibroblasts fair-weather friends? J Cardiovasc Transl Res (2012) 0.86
G protein-coupled receptor kinases in cardiovascular disease: why "where" matters. Trends Cardiovasc Med (2012) 0.85
EPAC regulation of cardiac EC coupling. J Physiol (2007) 0.84
Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol (2013) 0.84
Protein kinase Cδ mediates MCP-1 mRNA stabilization in vascular smooth muscle cells. Mol Cell Biochem (2010) 0.83
Y-box binding protein 1 and RNase UK114 mediate monocyte chemoattractant protein 1 mRNA stability in vascular smooth muscle cells. Mol Cell Biol (2012) 0.82
Mena associates with Rac1 and modulates connexin 43 remodeling in cardiomyocytes. Am J Physiol Heart Circ Physiol (2013) 0.81
Enhanced calcium cycling and contractile function in transgenic hearts expressing constitutively active G alpha o* protein. Am J Physiol Heart Circ Physiol (2008) 0.79
G protein coupled receptor kinase 2 interacting protein 1 (GIT1) is a novel regulator of mitochondrial biogenesis in heart. J Mol Cell Cardiol (2011) 0.78
PKC-ing is believing: targeting protein kinase C in heart failure. Circ Res (2011) 0.77
Gene expression profile of the recovering human heart. Eur Heart J (2007) 0.77
S100A1: Another Step Toward Therapeutic Development for Heart Failure. J Am Coll Cardiol (2011) 0.76
The future of endothelin-receptor antagonism as treatment for systemic hypertension. Curr Hypertens Rep (2006) 0.76
Advances in induced pluripotent stem cells, genomics, biomarkers, and antiplatelet therapy highlights of the year in JCTR 2013. J Cardiovasc Transl Res (2014) 0.76
G protein-coupled receptor kinase 5: exploring its hype in cardiac hypertrophy. Circ Res (2012) 0.75
Embracing bias: β1-adrenergic receptor-biased ligands and nuclear miRNA processing. Circ Res (2014) 0.75
Angiotensin II: a devious activator of mineralocorticoid receptor-dependent gene expression. Circ Res (2005) 0.75
G protein coupled receptor-mediated transactivation of extracellular proteases. J Cardiovasc Pharmacol (2017) 0.75
RNA extraction from healthy and failing human myocardium: a comparative evaluation. Biopreserv Biobank (2015) 0.75
Cardiac fibroblasts and cellular cross talk in heart failure. J Cardiovasc Transl Res (2012) 0.75